ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Interventional Highlights From LIBREXIA ACS, PREMIUM, SWITCH SWEDEHEART, A-CLOSE, EPIDAURUS
    Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission at the time of primary PCI in STEMI; switching from ticagrelor to prasugrel following PCI in patients with acute coronary syndrome (ACS); clopidogrel vs. extended […]
  • DAN-RSV: Analyses Compare RSVpreF Vaccine With No Vaccine
    Adults who received the bivalent RSV prefusion F (RSVpreF) vaccine, compared with no vaccine, had a lower incidence of hospitalizations for respiratory syncytial virus (RSV)-related respiratory illness, based on expanded findings from the DAN-RSV trial presented at ESC Congress 2026 and simultaneously published in NEJM Evidence.
  • JACC Journals’ Abstracts Explore Novel Therapies, Role of Precision Medicine, and More
    Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care.
  • REACT: Use of Imaging to Detect Silent Atherosclerosis in Early Adulthood
    Silent atherosclerosis is detectable using imaging in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and significant increases in plaque volume, based on results from the REACT trial presented at ESC Congress 2026 and simultaneously published in NEJM.
  • AMUNDSEN: Evolocumab vs. Standard Care in Lowering LDL-C Before PCI For Acute MI
    First-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction in patients with acute MI undergoing PCI, with more than 80% reaching the guideline recommended target of LDL-C less than 55 mg/dL at one year, said researchers presenting findings from the AMUNDSEN trial at ESC Congress 2026. However, no clinical benefit was […]